Name: EPTIFIBATIDE (IntegrilinR)
Classification: platelet glycoprotein IIb/IIIa receptor antagonist 
  • inhibits platelet aggregation 
  • indicated for preventing adverse thromboembolic phenomena in patients with unstable angina or non-Q-wave myocardial infarction and those undergoing percutaneous coronary intervention 
  • intended for use with heparin and aspirin  
Dose: IV Direct: 
  • 180 ug/kg as soon as possible following diagnosis; given IV push over 1-2 minutes 
  • follow immediately with continuous infusion 
Administration: IV Infusion: 
75 mg/100 ml vials
  • infuse at 2 ug/kg/min 
  • administer undiluted from vial 
  • continue infusion until discharge, initiation of coronary artery bypass grafting surgery or at discretion of physician for up to 72 hours; discontinue 4 hours prior to surgery 
  • if patient undergoes PTCA, infusion should be continued for up to 20-24 hours post procedure, for a total of 90-96 hours 
Integrilin Dosing Chart by Weight for Patients with Unstable Angina/Non-Q wave MI (180ug/kg Bolus and 2ug/kg/min Infusion)
     
     
    Patient Weight
    (kg)
    Bolus Volume in ml
    (2 mg/ml)
    Infusion Rate in ml/h
    (0.75mg/ml)
    37-41 3.4 6
    42-46 4 7
    47-53 4.5 8
    54-59 5 9
    60-65 5.6 10
    66-71 6.2 11
    72-78 6.8 12
    79-84 7.3 13
    85-90 7.9 14
    91-96 8.5 15
    97-103 9 16
    104-109 9.5 17
    110-115 10.2 18
    116-121 10.7 19
    >121  11.3 20
Contraindications:
  • in patients with history of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days 
  • severe hypertension (SBP>200 or DBP>110) not adequately controlled on antihypertensive therapy 
  • major surgery within the preceding 6 weeks 
  • history of stroke within 30 days or any history of hemorrhagic stroke 
  • platelet count < 100 
  • serum creatinine >165 or dependence on hemodialysis 
  • clinically significant liver disease 
Adverse Effects:
  • bleeding 
  • thrombocytopenia 
Caution:
  • should be used cautiously with other medications that affect hemostasis, including oral anticoagulants, non-steroidal antiinflammatories, dipyridamole, ticlopidine and clopidogrel 
Monitoring Therapy:
  • INR/PTT 
  • platelet count; hemoglobin 
  • bleeding 
  • ECG 
  • CCTC Protocol:
    • Must be administered by a physician. 
    • Should not be infused through the injection port of the right heart catheter. 
    • Must be administered as a continuous infusion via an infusion pump. 

    LHSCHealth Professionals

    Last Updated March 24, 2009 | © 2007, LHSC, London Ontario Canada